CA2085897A1 - Virus variant non pathogene - Google Patents

Virus variant non pathogene

Info

Publication number
CA2085897A1
CA2085897A1 CA002085897A CA2085897A CA2085897A1 CA 2085897 A1 CA2085897 A1 CA 2085897A1 CA 002085897 A CA002085897 A CA 002085897A CA 2085897 A CA2085897 A CA 2085897A CA 2085897 A1 CA2085897 A1 CA 2085897A1
Authority
CA
Canada
Prior art keywords
hiv
nonpathogenic
virus
variant
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002085897A
Other languages
English (en)
Inventor
George Pieczenik
Michael Scolaro
Roy Durham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUVAX
Original Assignee
IMMUVAX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUVAX filed Critical IMMUVAX
Publication of CA2085897A1 publication Critical patent/CA2085897A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002085897A 1990-06-19 1991-06-19 Virus variant non pathogene Abandoned CA2085897A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54052990A 1990-06-19 1990-06-19
US540,529 1990-06-19
US62595890A 1990-12-11 1990-12-11
US625,958 1990-12-11

Publications (1)

Publication Number Publication Date
CA2085897A1 true CA2085897A1 (fr) 1991-12-20

Family

ID=27066463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002085897A Abandoned CA2085897A1 (fr) 1990-06-19 1991-06-19 Virus variant non pathogene

Country Status (3)

Country Link
EP (1) EP0537247A4 (fr)
CA (1) CA2085897A1 (fr)
WO (1) WO1991019795A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015661A (en) * 1994-02-14 2000-01-18 The Macfarlane Burnet Centre For Medical Research Limited Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
IL112636A0 (en) * 1994-02-14 1995-05-26 Macfarlane Burnet Ctre Med Res Non-pathogenic strains of hiv-1
AU699175B2 (en) * 1994-02-14 1998-11-26 Australian Red Cross Society (Nsw Division) Non-pathogenic strains of HIV-1
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2590337C (fr) 2004-12-15 2017-07-11 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502161A (ja) * 1986-02-14 1988-08-25 アメリカ合衆国 ヒトｔ−細胞リンパ球指向性ウイルスタイプ３の複製を抑制するプラスミド
EP0242216A1 (fr) * 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Clone non cytopathique de virus lymphotropique de T-cellule humaine type III
JPH01120284A (ja) * 1987-11-05 1989-05-12 Shiro Kato Ｈｉｖ不完全粒子および該製造方法
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
JPH02203783A (ja) * 1989-02-02 1990-08-13 Banyu Pharmaceut Co Ltd 抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞

Also Published As

Publication number Publication date
EP0537247A1 (fr) 1993-04-21
WO1991019795A1 (fr) 1991-12-26
EP0537247A4 (en) 1993-09-08

Similar Documents

Publication Publication Date Title
Talagrand-Reboul et al. Relapsing fevers: neglected tick-borne diseases
Pardy et al. Analysis of the T cell response to Zika virus and identification of a novel CD8+ T cell epitope in immunocompetent mice
Zhang et al. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination
Rico-Hesse et al. Molecular evolution of dengue type 2 virus in Thailand
Schad et al. Predisposition to hookworm infection in humans
Armstrong et al. Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti
Dubbs et al. Mutant strains of herpes simplex deficient in thymidine kinase-inducing activity
CA2085897A1 (fr) Virus variant non pathogene
Shioda et al. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression
CN105567738A (zh) 使用基因组编辑技术CRISPR-Cas9诱导CCR5Δ32缺失的方法
KR101150584B1 (ko) 웨스트 나일 바이러스 백신
EA004921B1 (ru) Аттенуированный микроорганизм salmonella и способы его применения
Sciammas et al. TCRγδ cells and viruses
CN101056977B (zh) 用于治疗hiv感染患者的亚型匹配的灭活全病毒疫苗
Vickerman Trypanosome sociology and antigenic variation
Parvaneh et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency
US5747526A (en) Anti-HIV /Aids Chemo(C)-, immuno(I)-, or ci-therapy using tur (or related compounds) and/or NVA (or EPV)
JPH08504094A (ja) Ａ型肝炎ワクチン
EP0491930A1 (fr) Vaccins prepares a partir d'un lentivirus de primate.
Odoom et al. Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient
Mackel et al. Classical and γδ T cells are each independently sufficient to establish protection against a classical strain of Klebsiella pneumoniae
Dittmer et al. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge
US9795665B2 (en) Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
Turner Humoral and cellular immune responses of mice to rabies and smallpox vaccines
CN115998887A (zh) 一种结直肠癌合成致死基因对的应用

Legal Events

Date Code Title Description
FZDE Dead